Skip to main content
Clinical Trials/NCT02777957
NCT02777957
Unknown
Not Applicable

Predictors and Survival in Pulmonary Hypertension Associated With Severe Lung Disease

Silesian Centre for Heart Diseases1 site in 1 country200 target enrollmentDecember 2008

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pulmonary Hypertension
Sponsor
Silesian Centre for Heart Diseases
Enrollment
200
Locations
1
Primary Endpoint
Survival after the initial right heart catheterization (RHC) measurements
Last Updated
5 years ago

Overview

Brief Summary

First, the aim of the study was to evaluate the usefulness of echocardiographic parameters for detecting pulmonary hypertension (PH) in patients with advanced lung disease referred for lung transplantation. Second, to assess the prevalence of PH and to identify which hemodynamic, echocardiographic, pulmonary functional test, exercise capacity and biochemical parameters (especially NT-proBNP) have an impact on survival in a cohort of patients with severe lung diseases referred for lung transplantation.

Registry
clinicaltrials.gov
Start Date
December 2008
End Date
April 2023
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Silesian Centre for Heart Diseases
Responsible Party
Principal Investigator
Principal Investigator

Jolanta Nowak

MD, PhD

Silesian Centre for Heart Diseases

Eligibility Criteria

Inclusion Criteria

  • advanced lung disease
  • qualification for lung transplantation
  • written informed consent
  • pulmonary capillary wedge pressure \< 15 mmHg

Exclusion Criteria

  • history of idiopathic pulmonary hypertension,
  • primary valvular heart diseases,
  • coronary artery disease,
  • collagen vascular disease,
  • history or evidence of left ventricular dysfunction,
  • atrial fibrillation,
  • increased liver enzyme levels ( 3 times the upper laboratory limit),
  • renal dysfunction (estimated glomerular filtration rate \< 60 ml/min/1.73m2)
  • patients who didn't write the personal informed consent
  • any specific therapy for PH.

Outcomes

Primary Outcomes

Survival after the initial right heart catheterization (RHC) measurements

Time Frame: 1 year

Secondary Outcomes

  • Survival to lung transplantation or the end of the observation period after the initial right heart catheterization (RHC) measurement(3 years)

Study Sites (1)

Loading locations...

Similar Trials